Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review
Abstract
This systematic literature review assesses the cost-effectiveness and medication use in treating gangrene among patients with type 2 diabetes mellitus (T2DM). The review focuses on evaluating different treatment regimens and identifying key factors that influence cost-effectiveness outcomes. A total of 22 studies were analyzed to understand regional variations in treatment approaches and the cost-effectiveness of medications, including empagliflozin, semaglutide, and TLC-NOSF dressings, among others. The methodology involved a comprehensive search of databases for relevant studies published between 2019 and 2024. The search terms were selected based on the population, intervention, comparison, and outcomes (PICO) framework, with keywords such as “type 2 diabetes mellitus,” “gangrene,” “foot ulcers,” and “cost-effectiveness,” followed by an in-depth analysis using VOSviewer to map keyword trends and relationships. The search terms were selected based on the population, intervention, comparison, and outcomes (PICO) framework, with keywords such as “type 2 diabetes mellitus,” “gangrene,” “foot ulcers,” and “cost-effectiveness.”. The studies were evaluated based on their design, population characteristics, interventions, outcomes, and economic impact. The results showed significant geographic variations, with higher cost-effectiveness reported in developed countries due to better access to advanced treatments. Medications like empagliflozin and semaglutide consistently…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.